MX2009013646A - Metodos de diagnostico y tratamiento del cancer. - Google Patents

Metodos de diagnostico y tratamiento del cancer.

Info

Publication number
MX2009013646A
MX2009013646A MX2009013646A MX2009013646A MX2009013646A MX 2009013646 A MX2009013646 A MX 2009013646A MX 2009013646 A MX2009013646 A MX 2009013646A MX 2009013646 A MX2009013646 A MX 2009013646A MX 2009013646 A MX2009013646 A MX 2009013646A
Authority
MX
Mexico
Prior art keywords
methods
diagnosing
treating cancer
levels
rrm1
Prior art date
Application number
MX2009013646A
Other languages
English (en)
Spanish (es)
Inventor
Gerold Bepler
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Publication of MX2009013646A publication Critical patent/MX2009013646A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009013646A 2007-06-15 2008-06-13 Metodos de diagnostico y tratamiento del cancer. MX2009013646A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94415707P 2007-06-15 2007-06-15
US3955508P 2008-03-26 2008-03-26
PCT/US2008/066918 WO2008157353A1 (en) 2007-06-15 2008-06-13 Methods of diagnosing and treating cancer

Publications (1)

Publication Number Publication Date
MX2009013646A true MX2009013646A (es) 2010-03-30

Family

ID=40156627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013646A MX2009013646A (es) 2007-06-15 2008-06-13 Metodos de diagnostico y tratamiento del cancer.

Country Status (12)

Country Link
US (1) US20090017012A1 (cg-RX-API-DMAC7.html)
EP (1) EP2171086B1 (cg-RX-API-DMAC7.html)
JP (1) JP5479332B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100044780A (cg-RX-API-DMAC7.html)
CN (1) CN101815793A (cg-RX-API-DMAC7.html)
AU (1) AU2008266048A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0813364A2 (cg-RX-API-DMAC7.html)
CA (1) CA2690865A1 (cg-RX-API-DMAC7.html)
ES (1) ES2401475T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009013646A (cg-RX-API-DMAC7.html)
RU (1) RU2010101093A (cg-RX-API-DMAC7.html)
WO (1) WO2008157353A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877569A4 (en) * 2005-05-04 2009-07-15 Univ South Florida PREDICTING THE RESPONSE TO TREATMENT OF CANCER PATIENTS
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
BRPI0711011A2 (pt) 2006-05-18 2011-08-23 Molecular Profiling Institute, Inc. método para a determinação da intervenção médica para um estado de doença, método para a identificação de uma terapia de droga com capacidade de interação com um alvo molecular e sistema para a determinação da intervenção médica individualizada para um estado de doença
EP2730662A1 (en) * 2008-11-12 2014-05-14 Caris Life Sciences Luxembourg Holdings Methods and systems of using exosomes for determining phenotypes
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
JP5024736B2 (ja) 2009-10-15 2012-09-12 住友電気工業株式会社 発電システム
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
US10660965B2 (en) 2010-03-29 2020-05-26 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
KR101602532B1 (ko) * 2013-08-29 2016-03-11 경북대학교 산학협력단 위암의 재발 가능성 예측을 위한 정보제공 방법
US20180312928A1 (en) * 2015-10-26 2018-11-01 Cipherome Method and system for selecting customized drug using genomic nucleotide sequence variation information and survival information of cancer patient
AU2021305654A1 (en) * 2020-07-10 2023-03-02 Progenics Pharmaceuticals, Inc Methods of making prostate cancer treatment decisions
CN113957145B (zh) * 2021-10-19 2023-09-26 中国医学科学院肿瘤医院 m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用
CN114564622B (zh) * 2022-03-03 2025-07-25 苏州良医汇网络科技有限公司 一种tnm分期表录入系统的方法、装置以及设备

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705336A (en) * 1995-03-07 1998-01-06 The United States Of America As Represented By The Department Of Health And Human Services Assay for sensitivity of tumors to DNA-platinating chemotherapy
US20020090642A1 (en) * 1995-12-11 2002-07-11 Patrick G. Johnston Methods for determining the prognosis of breast cancer using antibodies specific for thymidylate synthase
WO1998033518A1 (en) * 1997-02-04 1998-08-06 Sloan-Kettering Institute For Cancer Research Mutants of thymidylate synthase and uses thereof
US6087489A (en) * 1998-06-02 2000-07-11 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of human thymidylate synthase expression
AU5569600A (en) * 1999-06-28 2001-01-31 Yusuke Nakamura Novel protein and dna thereof
US6248535B1 (en) * 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6518416B1 (en) * 2000-12-01 2003-02-11 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US7049059B2 (en) * 2000-12-01 2006-05-23 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US6582919B2 (en) * 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6956111B2 (en) * 2001-03-02 2005-10-18 Response Genetics, Inc. Method of determining dihydropyrimidine dehydrogenase gene expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
US7919235B2 (en) * 2002-09-30 2011-04-05 F. Hoffman-La Roche Ag Oligonucleotides for genotyping thymidylate synthase gene
JP2007507770A (ja) * 2003-09-29 2007-03-29 パスワーク インフォーマティクス，インコーポレーテッド 生物学的特徴を検出するためのシステムおよび方法
EP1877569A4 (en) * 2005-05-04 2009-07-15 Univ South Florida PREDICTING THE RESPONSE TO TREATMENT OF CANCER PATIENTS

Also Published As

Publication number Publication date
KR20100044780A (ko) 2010-04-30
ES2401475T3 (es) 2013-04-19
CA2690865A1 (en) 2008-12-24
AU2008266048A1 (en) 2008-12-24
JP2010530746A (ja) 2010-09-16
JP5479332B2 (ja) 2014-04-23
CN101815793A (zh) 2010-08-25
WO2008157353A1 (en) 2008-12-24
EP2171086A4 (en) 2010-10-13
EP2171086A1 (en) 2010-04-07
BRPI0813364A2 (pt) 2014-12-30
RU2010101093A (ru) 2011-07-20
EP2171086B1 (en) 2012-12-19
US20090017012A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
MX2009013646A (es) Metodos de diagnostico y tratamiento del cancer.
WO2019213282A8 (en) Biomarkers for evaluating car-t cells to predict clinical outcome
WO2011015944A3 (en) Use of free dna as an early predictor of severity in acute pancreatitis
WO2010004591A3 (en) Genetic variants for breast cancer risk assessment
WO2008008500A3 (en) Methods for making cancer prognoses based on the subcellular localization of biomarkers
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2010018601A3 (en) Genetic variants predictive of cancer risk
WO2007053648A3 (en) Compositions and methods for treating and diagnosing cancer
WO2008061213A3 (en) Genetic variations associated with tumors
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
NZ591613A (en) Polymorphic marker rs965513 for risk assessment of thyroid cancer
WO2008036691A3 (en) Biomarkers for prostate cancer and methods using the same
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008061104A3 (en) Methods and kits for detecting prostate cancer biomarkers
WO2008117314A3 (en) Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2007123772A3 (en) Genes involved in estrogen metabolism
WO2003101400A3 (en) Cancer-linked gene as target for chemotherapy
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
MX2009007458A (es) Biomarcador para la medicina y la biologia de la reproduccion.
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2007034221A3 (en) Non small cell lung cancer therapy prognosis and target
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
MX2009005058A (es) Metodos para tratar, diagnosticar o detectar cancer.
MX339340B (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.
MX2009004382A (es) Variaciones geneticas asociadas con tumores.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal